JP2013529071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529071A5 JP2013529071A5 JP2013505490A JP2013505490A JP2013529071A5 JP 2013529071 A5 JP2013529071 A5 JP 2013529071A5 JP 2013505490 A JP2013505490 A JP 2013505490A JP 2013505490 A JP2013505490 A JP 2013505490A JP 2013529071 A5 JP2013529071 A5 JP 2013529071A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- snp
- item
- individual
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 83
- 102000001690 Factor VIII Human genes 0.000 claims description 69
- 108010054218 Factor VIII Proteins 0.000 claims description 69
- 229960000301 factor viii Drugs 0.000 claims description 69
- 238000009007 Diagnostic Kit Methods 0.000 claims description 34
- 108091034117 Oligonucleotide Proteins 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 208000031220 Hemophilia Diseases 0.000 claims description 15
- 208000009292 Hemophilia A Diseases 0.000 claims description 15
- 238000002493 microarray Methods 0.000 claims description 14
- 229940030225 antihemorrhagics Drugs 0.000 claims description 12
- 239000002874 hemostatic agent Substances 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000009396 hybridization Methods 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 238000012175 pyrosequencing Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 5
- 230000001105 regulatory effect Effects 0.000 claims 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32660210P | 2010-04-21 | 2010-04-21 | |
| US61/326,602 | 2010-04-21 | ||
| PCT/EP2011/056471 WO2011131774A1 (en) | 2010-04-21 | 2011-04-21 | Genetic factors associated with inhibitor development in hemophilia a |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015183020A Division JP6189904B2 (ja) | 2010-04-21 | 2015-09-16 | 血友病ａにおけるインヒビターの発達と関連する遺伝因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013529071A JP2013529071A (ja) | 2013-07-18 |
| JP2013529071A5 true JP2013529071A5 (https=) | 2014-06-05 |
| JP6058529B2 JP6058529B2 (ja) | 2017-01-11 |
Family
ID=43983253
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505490A Active JP6058529B2 (ja) | 2010-04-21 | 2011-04-21 | 血友病ａにおけるインヒビターの発達と関連する遺伝因子 |
| JP2015183020A Active JP6189904B2 (ja) | 2010-04-21 | 2015-09-16 | 血友病ａにおけるインヒビターの発達と関連する遺伝因子 |
| JP2017151073A Active JP6568162B2 (ja) | 2010-04-21 | 2017-08-03 | 血友病ａにおけるインヒビターの発達と関連する遺伝因子 |
| JP2019142337A Withdrawn JP2019180421A (ja) | 2010-04-21 | 2019-08-01 | 血友病ａにおけるインヒビターの発達と関連する遺伝因子 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015183020A Active JP6189904B2 (ja) | 2010-04-21 | 2015-09-16 | 血友病ａにおけるインヒビターの発達と関連する遺伝因子 |
| JP2017151073A Active JP6568162B2 (ja) | 2010-04-21 | 2017-08-03 | 血友病ａにおけるインヒビターの発達と関連する遺伝因子 |
| JP2019142337A Withdrawn JP2019180421A (ja) | 2010-04-21 | 2019-08-01 | 血友病ａにおけるインヒビターの発達と関連する遺伝因子 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9637789B2 (https=) |
| EP (2) | EP2730663B1 (https=) |
| JP (4) | JP6058529B2 (https=) |
| AU (1) | AU2011244228B2 (https=) |
| CA (2) | CA2796561C (https=) |
| ES (1) | ES2949953T3 (https=) |
| WO (1) | WO2011131774A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010290131C1 (en) | 2009-08-24 | 2015-12-03 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
| AU2011244228B2 (en) * | 2010-04-21 | 2015-07-30 | Jan Astermark | Genetic factors associated with inhibitor development in hemophilia A |
| BR112014020694A2 (pt) | 2012-02-15 | 2018-05-08 | Amunix Operating Inc. | proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a |
| CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
| KR101774996B1 (ko) * | 2016-06-23 | 2017-09-19 | 주식회사 녹십자지놈 | 혈우병 치료제의 효능 예측 마커 및 이의 용도 |
| IL319473A (en) | 2016-12-02 | 2025-05-01 | Bioverativ Therapeutics Inc | Methods for treating hemophilic arthritis using chimeric blood clotting factors |
| BR112020022164A2 (pt) | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | métodos de tratamento de hemofilia a |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| JP4071277B2 (ja) | 1993-11-12 | 2008-04-02 | ピーエイチアールアイ・プロパティーズ・インコーポレーテッド | 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット |
| AU710425B2 (en) | 1995-12-18 | 1999-09-23 | Washington University | Method for nucleic acid analysis using fluorescence resonance energy transfer |
| WO2008059009A2 (en) * | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Factor v mutants for hemostasis in hemophilia |
| AU2011244228B2 (en) * | 2010-04-21 | 2015-07-30 | Jan Astermark | Genetic factors associated with inhibitor development in hemophilia A |
-
2011
- 2011-04-21 AU AU2011244228A patent/AU2011244228B2/en active Active
- 2011-04-21 CA CA2796561A patent/CA2796561C/en active Active
- 2011-04-21 EP EP14154482.5A patent/EP2730663B1/en active Active
- 2011-04-21 US US13/091,968 patent/US9637789B2/en active Active
- 2011-04-21 ES ES14154482T patent/ES2949953T3/es active Active
- 2011-04-21 CA CA3050896A patent/CA3050896C/en active Active
- 2011-04-21 WO PCT/EP2011/056471 patent/WO2011131774A1/en not_active Ceased
- 2011-04-21 JP JP2013505490A patent/JP6058529B2/ja active Active
- 2011-04-21 EP EP11715562A patent/EP2561090A1/en not_active Withdrawn
- 2011-08-10 US US13/207,286 patent/US9644239B2/en active Active
-
2015
- 2015-09-16 JP JP2015183020A patent/JP6189904B2/ja active Active
-
2017
- 2017-03-14 US US15/458,878 patent/US20180016635A1/en not_active Abandoned
- 2017-08-03 JP JP2017151073A patent/JP6568162B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142337A patent/JP2019180421A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529071A5 (https=) | ||
| JP6700333B2 (ja) | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 | |
| US20220056534A1 (en) | Methods for analysis of circulating cells | |
| KR101177320B1 (ko) | Ｙ형 프로브 및 이것의 변형형, 및 이를 이용한 ｄｎａ 마이크로어레이, 키트 및 유전자 분석방법 | |
| CN119032182A (zh) | 用于癌症检测和监测的方法 | |
| JP2014204730A5 (https=) | ||
| WO2004042057A1 (ja) | 遺伝子変異検出法 | |
| JP6568162B2 (ja) | 血友病ａにおけるインヒビターの発達と関連する遺伝因子 | |
| CN105431738B (zh) | 胃癌的预后预测模型的建立方法 | |
| KR20150042882A (ko) | 개인맞춤약물 적용을 위한 한국인 약물유전형 동시다중분석 및 분석 결과를 활용한 약물반응 예측 방법 | |
| CN107475371A (zh) | 发现药物基因组生物标志物的方法 | |
| JP2010512729A (ja) | 癌リスクの層別化のための遺伝的モデル | |
| JP2009148269A (ja) | 微量胃癌細胞の検出法 | |
| TW201812125A (zh) | 使用藥物基因體學標記的組合物及方法 | |
| JP2005532780A (ja) | 発癌リスク層別化のための遺伝的解析 | |
| JP2009504153A (ja) | オリゴヌクレオチド設計および／または核酸検出の方法および／または装置 | |
| CN104152556B (zh) | 一种判断曲妥珠单抗辅助治疗乳腺癌疗效的试剂盒及应用 | |
| JP2007503836A (ja) | 癌のリスク層別化のための遺伝的解析法 | |
| Papatheodorou et al. | Development of a novel microarray methodology for the study of SNPs in the promoter region of the TNF-α gene—Their association with obstructive pulmonary disease in Greek patients | |
| Dwivedi et al. | Molecular biotechnology for diagnostics | |
| JP5866669B2 (ja) | 乳がん発症感受性の判定方法 | |
| KR101724130B1 (ko) | 장 베체트병 진단용 바이오마커 및 이의 용도 | |
| CN104789673B (zh) | rs1800818在检测新布尼亚病毒引起的发热伴血小板减少综合征中的应用 | |
| CN104120188B (zh) | 手足综合症易感性检测试剂盒和snp在其制备中的应用 | |
| KR101213173B1 (ko) | 유방암과 연관된 단일염기다형성 및 그의 용도 |